Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock Score, Valuation & Financial Research

Shuttle Pharmaceuticals Holdings, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SHPH

Shuttle Pharmaceuticals Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.06. These figures are a research snapshot, not a buy or sell recommendation.

What Shuttle Pharmaceuticals Holdings, Inc. does

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing radiation sensitizers to improve cancer treatment outcomes. Following the November 2025 acquisition of Molecule.ai, the company also operates an AI-driven platform for molecular discovery and early-stage drug development, seeking to generate revenue through software licensing and service agreements.

Products and services

  • The company's primary product candidate is Ropidoxuridine, a radiation sensitizer. Additionally, it offers an AI-driven platform for molecular discovery and drug development through its Molecule.ai business unit.

Brands and product families

  • Molecule.ai — AI-driven platform for molecular discovery and early-stage drug development. Source
  • Ropidoxuridine — Lead clinical-stage radiation sensitizer candidate. Source

Customer types

Pharmaceutical and biotechnology companies; Academic and research institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and preclinical studies. Source

Competitors and product-market comparisons

  • Radiation therapy and oncology drug developers — Various pharmaceutical and biotechnology companies developing radiation sensitizers or competing oncology therapies. Source

Business strengths to evaluate

  • Proprietary AI-driven molecular discovery platform Source
  • Clinical-stage pipeline for radiation sensitizers Source

Business risks and research considerations

  • Substantial doubt regarding ability to continue as a going concern Source
  • History of operating losses and lack of revenue Source
  • Risks associated with integration of acquired assets and technologies Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SHPH financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.06
Market capitalization:
2.38M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.26M
Free cash flow:
USD -9.48M
Cash:
USD 90.24K
Total debt:
USD 195.16K
EPS:
USD -30.80

What stands out

  • Free cash flow is USD -9.48M, negative for the stored period.
  • The balance sheet shows USD 90.24K of cash versus USD 195.16K of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 104.92K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SHPH

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SHPH fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is SHPH's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for SHPH to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SHPH's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SHPH

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.